期刊文献+

硼替佐米治疗淋巴瘤的疗效评价

下载PDF
导出
摘要 目的评价硼替佐米治疗淋巴瘤的临床效果。方法选取我院2010年2月-2012年10月收治的6例非霍奇金淋巴瘤患者进行硼替佐米治疗,观察其临床症状改善情况及不良反应发生情况。结果 6例患者中病情完全缓解2例,部分缓解4例,用药治疗过程中2例患者有乏力症状,5例患者的血小板计数明显减少,3例患者有恶心呕吐的肠道不良反应,1例患者有神经性病变,对症处理后患者的不良反应消失。结论淋巴瘤患者应用硼替佐米治疗有着良好的应用效果,可以在临床上应用推广。
作者 许惠丽
出处 《中国医学工程》 2014年第11期172-172,共1页 China Medical Engineering
  • 相关文献

参考文献3

二级参考文献33

  • 1刘辉,金洁.硼替佐米治疗非霍奇金淋巴瘤的展望[J].国际输血及血液学杂志,2006,29(3):263-265. 被引量:2
  • 2Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells[J]. Proc Natl Acad Sci USA,2002,99(22). 14374-14379.
  • 3Paoluzzi L, O'Connor OA. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas[J]. Bio Drugs,2006,20 (1):13-23.
  • 4Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitorbortezomib in relapsed or refractory B-cell non-hodgkin's lymphoma[J]. Journal of Clinical Oncology, 2005,23(4):667-675.
  • 5O'Connor OA, Wright J, Moskowitz C, et al. Phase Ⅱ clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-hodgkin's lymphoma and mantle cell lymphoma[J]. Journal of Clinical Oncology, 2005,23(4):676-684.
  • 6Goy A, Hart S, Pro B, et al. Report of a phase Ⅱ study ofproteasome inhibitor bortezomib (Velcade) in patients with relapsed or refractory indolent or aggressive lymphoma[J]. Blood, 2003,1020:627.
  • 7Fisher RI, Bernstein SH, Kahl BS,et al. Multicenter phase Ⅱstudy of bortezomib in patients with relapsed or refractory mantle cell lymphoma [J]. Journal of Clinical Oncology, 2006,24 (30):4867-4874.
  • 8Koc ON, Bahlis N J, Liu L, et al. A phase I trial of bortezomib in combination with fludarabine in patients with lymphoproliferative neoplasms[J]. Journal of Clinical Oncology, 2005,23(16):6647.
  • 9Dunleavy K, Janik J, Gea-Banacloche J, et al. Phase Ⅰ/Ⅱ study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refraclory aggressive B-cell lymphoma[J]. Blood (ASH Annual Meeting Abstracts) ,2004,104(9): 1385-1392.
  • 10De Vos S, Dakhil S, McLaughlin P, et al. Bortezomib plus rituximab in patients with indolent non-hodgkin' s lymphoma (NHL): a phase 2 study[J]. Blood (ASH Annuzd Meeting Abstracts), 2005,106:17.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部